Using muscle relaxants to improve electroporation ablation safety
The Use of Muscle Relaxants During Electroporation Ablation (PFA) as a Potential Protective Factor Against Damage to Transverse Striated Muscle Tissue and the Heart
NA · 4th Military Clinical Hospital with Polyclinic, Poland · NCT06707532
This study tests if using muscle relaxants during a heart procedure called electroporation ablation can make it safer for patients and help them recover faster.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 32 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | 4th Military Clinical Hospital with Polyclinic, Poland (other) |
| Locations | 1 site (Wroclaw, Lower Silesian Voivodeship) |
| Trial ID | NCT06707532 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of muscle relaxants during electroporation ablation (PFA) to enhance patient safety by minimizing skeletal muscle damage and assessing myocardial damage. Patients will be randomized into two groups: one receiving general anesthesia without muscle relaxants and the other with rocuronium. The study aims to improve the quality of the PFA procedure and accelerate recovery times. A total of 32 patients will participate, with a double-blind design to ensure unbiased results.
Who should consider this trial
Good fit: Ideal candidates are patients requiring PFA ablation for cardiac indications who can provide informed consent.
Not a fit: Patients with allergies to the anesthetics used or genetic neuromuscular diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to safer and more effective electroporation ablation procedures for patients with cardiac conditions.
How similar studies have performed: While the use of muscle relaxants in similar procedures has been explored, this specific application in electroporation ablation is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation Exclusion Criteria: * Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.
Where this trial is running
Wroclaw, Lower Silesian Voivodeship
- 4th Military Clinical Hospital with Polyclinic — Wroclaw, Lower Silesian Voivodeship, Poland (RECRUITING)
Study contacts
- Principal investigator: Marek Szamborski, MD — Senior Assistant
- Study coordinator: Marek Szamborski, MD
- Email: mszamborski@4wsk.pl
- Phone: 698-448-639
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Kidney Failure, Acute, Myopathy, Drugs, Heart Arrhythmia, Succinylcholine Sensitivity, Muscle Relaxation, General Anesthetic Drug Adverse Reaction, Projection